After Hours Gainer
IBRX Immunitybio7.76-0.24-3.0%
After Hours:8.00+0.24 (+3.1%)
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
Business WireTue, 19-May 8:30 PM
After Hours:7.98+0.22 (+2.8%)
IBRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
NewsfileTue, 19-May 4:42 PM
IBRX 7.14+0.04 (+0.6%)Immunitybio